CapVest closed the STADA Arzneimittel acquisition at €5.3 billion enterprise value, marking Europe's largest leveraged buyout in 2025 and the London firm's entry into deals typically reserved for Blackstone, KKR, and CVC. The transaction settled without a syndicate of co-investors, unusual for a deal of this scale in the current rate environment. STADA, a German generics and over-the-counter pharmaceutical manufacturer with operations in 50 countries, had been held by Bain Capital and Cinven since a €4.3 billion take-private in 2017.
The acquisition shifts CapVest from a €6 billion AUM mid-market operator into the bulge-bracket conversation. The firm structured the deal with €2.1 billion in equity and €3.2 billion in debt, achieving 60 percent leverage without tapping the high-yield market. Senior lenders included Deutsche Bank, BNP Paribas, and Goldman Sachs, who underwrote the package at 5.8 percent weighted average cost. CapVest did not use mezzanine financing or preferred equity, keeping the capital structure clean for operational flexibility. STADA generated €3.7 billion in revenue and €620 million EBITDA over the trailing twelve months, putting the purchase at 8.5x EBITDA before synergies.
This matters because mid-market firms rarely execute solo on deals above €3 billion in the post-ZIRP world. CapVest's ability to close without club-deal dilution signals either exceptional LP confidence or aggressive internal return assumptions. The firm's prior investments in European healthcare—including a €1.2 billion exit of Aenova in 2022 at 2.8x cash-on-cash—gave it operational credibility with debt arrangers. STADA's asset-light model and geographic diversification allowed higher leverage than typical pharmaceutical LBOs, which average 4.5x debt-to-EBITDA in Western Europe. The company has no patent cliff exposure and generates 72 percent of revenue from branded generics with 18 percent EBITDA margins, stable enough for lenders to underwrite without sponsor co-investment.
Allocators should track three near-term indicators. First, whether CapVest refinances the acquisition debt within 18 months through a dividend recapitalization, which would confirm the deal was underwritten to private credit standards rather than traditional bank terms. Second, if STADA announces bolt-on acquisitions in Q2 2025, particularly in Central and Eastern Europe where the company has 34 percent market share in generics. Third, CapVest's next fundraise, expected in late 2025, will test whether this deal was opportunistic or marks a permanent move upmarket. The firm has not yet announced a Fund VI target size.
The debt arrangers priced the senior facility at 450 basis points over EURIBOR, tight for a 60 percent levered deal but justified by STADA's 92 percent revenue visibility from long-term supply contracts with European health systems. The company has no U.S. exposure, insulating it from FDA approval volatility and dollar-euro swings that have compressed margins for European pharma exporters. CapVest's bet is that generic drug demand in aging European populations will grow at 6 percent annually through 2030, regardless of reimbursement pressure, and that STADA's fragmented market position allows 200-300 basis points of margin expansion through procurement scale.